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ABSTRACT
Introduction Left untreated, sexually transmitted and 
genital infections (henceforth STIs) in pregnancy can lead 
to serious adverse outcomes for mother and child. Papua 
New Guinea (PNG) has among the highest prevalence of 
curable STIs including syphilis, chlamydia, gonorrhoea, 
trichomoniasis and bacterial vaginosis, and high neonatal 
mortality rates. Diagnosis and treatment of these STIs 
in PNG rely on syndromic management. Advances in 
STI diagnostics through point- of- care (PoC) testing 
using GeneXpert technology hold promise for resource- 
constrained countries such as PNG. This paper describes 
the planned economic evaluation of a cluster- randomised 
cross- over trial comparing antenatal PoC testing and 
immediate treatment of curable STIs with standard 
antenatal care in two provinces in PNG.
Methods and analysis Cost- effectiveness of the PoC 
intervention compared with standard antenatal care will be 
assessed prospectively over the trial period (2017–2021) 
from societal and provider perspectives. Incremental 
cost- effectiveness ratios will be calculated for the primary 
health outcome, a composite measure of the proportion of 
either preterm birth and/or low birth weight; for life years 
saved; for disability- adjusted life years averted; and for 
non- health benefits (financial risk protection and improved 
health equity). Scenario analyses will be conducted to 
identify scale- up options, and budget impact analysis 
will be undertaken to understand short- term financial 
impacts of intervention adoption on the national budget. 
Deterministic and probabilistic sensitivity analysis will be 
conducted to account for uncertainty in key model inputs.
Ethics and dissemination This study has ethical 
approval from the Institutional Review Board of the PNG 
Institute of Medical Research; the Medical Research 
Advisory Committee of the PNG National Department of 
Health; the Human Research Ethics Committee of the 
University of New South Wales; and the Research Ethics 
Committee of the London School of Hygiene and Tropical 
Medicine. Findings will be disseminated through national 
stakeholder meetings, conferences, peer- reviewed 
publications and policy briefs.
Trial registration number ISRCTN37134032.
INTRODUCTION
In 2017, it was estimated that every day, glob-
ally, more than 1 million people acquire any 
of the four common curable sexually trans-
mitted infections: chlamydia, gonorrhoea, 
syphilis and trichomoniasis.1–3 Left untreated, 
sexually transmitted and genital infections 
Strengths and limitations of this study
 ► This protocol will assist in designing economic 
evaluations for similar complex public health inter-
ventions, especially those that seek to capture both 
health and non- health impacts of point- of- care test-
ing for sexually transmitted infections in low- and 
middle- income countries (LMICs).
 ► This protocol follows the Consolidated Health Economic 
Evaluation Reporting Standards, and guidelines from 
the Global Health Cost Consortium to design and re-
port economic evaluations nested in a randomised 
controlled trial and will include individual- level patient 
cost and health service use data.
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such as bacterial vaginosis (henceforth, referred to as 
STIs) are associated with adverse pregnancy and birth 
outcomes including spontaneous abortion, miscarriage, 
stillbirth, pre- term birth, low birth weight, postpartum 
endometritis, premature rupture of membranes, and 
various sequelae in newborn infants owing to mother- to- 
child transmission such as ophthalmia neonatorum.4–13
In Papua New Guinea (PNG), prevalence of STIs is 
high in the general population and among pregnant 
women.14 Clinical studies in PNG show that around 50% 
of all pregnant women test positive for one or more STIs 
at their first antenatal care (ANC) visit,6 15 with gonor-
rhoea, chlamydia, trichomoniasis and bacterial vaginosis 
most commonly diagnosed.5 6 15 16 There is evidence from 
resource- constrained settings to suggest that increased 
screening for HIV and syphilis in pregnancy is correlated 
with a reduction in perinatal and infant morbidity and 
mortality.17 18 In this high- burden and low- resource 
setting, poor access to ANC leads to missed opportunities 
for early diagnosis and clinical intervention.19
Traditional STI diagnosis for infections other than HIV 
and syphilis relies on microscopy, culture, and/or serology 
that require technical resources and expertise that may 
not be readily available in all low- and middle- income 
country (LMIC) settings.20 21 The long waiting period for 
results also deters some people from returning to collect 
their results.22 In settings where laboratory services are 
not available, syndromic management, which relies on 
clinical presentation, is most often used to inform treat-
ment decisions. This strategy fails to accurately identify 
causative pathogens or detect asymptomatic infections, 
and consequently leads to negligible impact on health 
outcomes.22 23 The development of accurate rapid diag-
nostic tests for HIV and syphilis used at point- of- care 
(PoC) has improved their detection, testing coverage 
and the number of patients accurately diagnosed and 
treated.24–26 From an equity standpoint, PoC testing has 
been shown to improve access to testing and treatment 
particularly among remote and hard- to- reach popula-
tions.24 27 However, the success of HIV and syphilis PoC 
diagnosis is yet to be replicated for other common curable 
STIs, including chlamydia and gonorrhoea.28–32
The Women and Newborn Trial of Antenatal Inter-
ventions and Management (WANTAIM) study is the 
first randomised trial to evaluate the effectiveness and 
cost- effectiveness of PoC STI testing and treatment to 
improve birth outcomes in high- burden settings.33 This 
paper aims to describe the rationale and methodological 
approach for the economic evaluation of this large- scale 
trial involving 4600 pregnant women in PNG.
In recent years, the evidence base for the cost and cost- 
effectiveness of PoC testing for STIs in pregnancy has 
grown, including in LMICs. A recent systematic review34 
identified that the bulk of these studies was conducted in 
Africa or Latin and South America,35–49 with no studies 
undertaken in East Asia or the Pacific. Most of the studies 
investigated the cost and cost- effectiveness of PoC testing 
for syphilis in pregnancy compared with no screening, 
syndromic management or onsite laboratory testing. 
Only one study evaluated testing for HIV and testing and 
treatment for syphilis,46 another for chlamydia,39 and 
none evaluated testing for gonorrhoea, trichomoniasis 
or bacterial vaginosis. Few studies evaluated the costs 
and cost- effectiveness of the test and treatment package 
combined. Despite widespread acknowledgement of the 
high out- of- pocket costs incurred by women and their 
families in accessing testing and treatment in many 
LMICs, the studies in the review were largely conducted 
from the provider perspective.35 38–41 43 47–49 Further, 
none of the studies presented estimates of affordability 
or budget impact and none analysed non- health- related 
outcomes such as equity or financial risk protection.50
STUDY SETTING
Papua New Guinea
In PNG, pregnant women and their infants experience 
a high burden of adverse health outcomes, with PNG 
recording one of the highest maternal mortality ratios 
and neonatal mortality rates in the world: 584 per 100 000 
and 25 per 1000 live births, respectively, compared with 
global figures of 209 and 18.51 52 In 2012, 20% of births in 
PNG were preterm birth and/or low birth weight, both 
key contributors to neonatal mortality.53
Pregnant women in PNG experience a high burden 
of curable STIs. Findings from a country- wide bio- 
behavioural survey of STIs in pregnancy indicated that 
the prevalence of chlamydia was 23%, gonorrhoea 14% 
and trichomoniasis 22%, with 44% of women having at 
least one of these infections.5 Another study evaluating 
the feasibility of a novel PoC testing and treatment 
strategy for STIs in PNG found that 54% of women had 
one or more of chlamydia, gonorrhoea, trichomoniasis 
or bacterial vaginosis, and the prevalence rates of each of 
these STIs were 19%, 11%, 38% and 18%, respectively.20 
Similar prevalence rates of STIs were observed in a study 
of malaria prevention in pregnancy.6 In these studies, 
between 65% and 80% of infections among pregnant 
women were asymptomatic indicating the need for more 
accurate diagnosis at PoC.
In PNG, national guidelines for ANC state that PoC 
testing and treatment for HIV and syphilis should be 
Strengths and limitations of this study
 ► The planned budget impact and affordability analyses will contribute 
to the understanding of fiscal space for investments in maternal and 
child health at provincial and country levels.
 ► This analysis builds on conventional cost- effectiveness analysis by in-
cluding non- health benefits such as financial risk protection that are 
key criteria for equitable resource allocation, and the design of health 
benefit packages in many LMICs including Papua New Guinea.
 ► The planned analyses for the base case scenario adopt only a 12- month 
time horizon but we propose to model the costs and benefits over the 
lifetime of mother and their babies using published data.
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undertaken for all pregnant women at the first ANC clinic 
visit. For women who test positive, treatment according 
to national guidelines is offered along with partner 
testing.54 However, despite the high prevalence of chla-
mydia, gonorrhoea, trichomoniasis and bacterial vagi-
nosis among pregnant women, detection and treatment 
rely on syndromic management according to national 
guidelines.54
Health services in PNG
In PNG, health services are organised into seven levels 
of care. Levels 1–4 offer primary care at community aid 
posts, subhealth centres, health centres, and rural/district 
hospitals. The majority of level 1–3 facilities are managed 
and staffed by health extension officers, nursing officers, 
midwives and community health workers; level 4 facili-
ties, that is, rural/district hospitals usually have a doctor 
on staff. Population coverage varies from about 5000 to 
20 000 per facility and the average distance travelled to 
reach a facility is 7–8 km. Secondary level care is provided 
at provincial/regional/national referral hospitals (levels 
5–7), which cover an average population of 200 000 and 
300 000 in one or more provinces.55 56 Health workforce 
distribution is suboptimal, with 0.5 physicians per 10 000 
population,57 compared with the WHO recommended 
ratio of 10 physicians per 10 000 population.58 Health-
care is predominantly provided by public health facil-
ities that are either financed and operated by the PNG 
government or by churches with financial support from 
the government.59
The WANTAIM trial
WANTAIM aims to test the effectiveness of antenatal PoC 
testing and treatment for STIs to improve maternal and 
newborn outcomes in PNG. WANTAIM is being imple-
mented in two provinces in PNG—Madang and East New 
Britain. Data collection continues despite the challenges 
of the COVID-19 pandemic, and the trial is due to finish 
in late 2021.33
WANTAIM is a cluster- randomised cross- over trial and 
the unit of randomisation is a primary healthcare centre 
and its catchment area. Ten geographically distinct clus-
ters have been assigned in a 1:1 ratio to intervention and 
control arms in the first phase of the trial. The end of 
the first phase of the trial is followed by a short washout 
period of 2–3 months, at the end of which each cluster 
will cross over to participate in the alternative trial arm 
in the second phase. The study participants are women 
attending their first ANC visit, aged over 16 years and 
less than 26 weeks’ gestation (assessed by ultrasound) 
(n=4600). Newborn infants are followed up within 72 
hours of birth.
Pregnant women recruited into the study receive 
routine ANC as per PNG national guidelines including 
sulfadoxine/pyrimethamine for malaria prevention; 
iron and folate supplementation; tetanus toxoid immu-
nisation; HIV and syphilis screening (and treatment 
if required). Women in the control arm receive STI 
syndromic management if they report symptoms of a 
genital infection (abdominal pain, discharge). They also 
provide a urine sample for diagnostic testing on GeneX-
pert in the study laboratory. If positive for STI at their 
last test, they receive treatment during the first postnatal 
visit. Women in the intervention arm of the trial provide 
a self- collected vaginal specimen for PoC STI testing, and 
same- day treatment as necessary, at the following time 
points:
 ► At enrolment (<26 weeks’ gestation).
 ► One month after trial enrolment.
 ► At 34–36 weeks’ antenatal follow- up.
The primary outcome of the trial is a composite 
measure of two events, the proportion of women and 
their newborn infants in each trial arm who experience 
either a preterm birth (<37 weeks’ gestation) and/or low 
birth weight (<2500 g).
The study has ethical approval from the Institutional 
Review Board (IRB) of the PNG Institute of Medical 
Research (IRB number 1608); the Medical Research Advi-
sory Committee (MRAC) of the PNG National Depart-
ment of Health (MRAC number 16.24); the Human 
Research Ethics Committee (HREC) of the University 
of New South Wales (HREC number 16708); and the 
Research Ethics Committee (REC) of the London School 
of Hygiene and Tropical Medicine (REC number 12009).
A full description of the WANTAIM intervention and 
trial design is described elsewhere.33 The purpose of this 
paper is to fully describe the methods for the economic 
evaluation of the trial.
AIMS AND OBJECTIVES
The economic evaluation aims to assess the cost- 
effectiveness and affordability of PoC testing and treat-
ment of curable STIs in pregnancy compared with 
standard care from a provider and societal perspective. 
The specific objectives of the economic evaluation are to:
1. Estimate total financial and economic costs of the PoC 
STI intervention.
2. Model incremental cost- effectiveness of the interven-
tion compared with standard care.
3. Extend the incremental cost- effectiveness analysis 
(CEA) to include equity- related measures of impact.
4. Conduct a budget impact analysis to assess the afford-
ability of implementing the intervention at the nation-
al level or in target areas/populations.
These planned analyses will adhere to the Consoli-
dated Health Economic Evaluation Reporting Standards 
and established guidelines from the Global Health Cost 
Consortium for conducting and reporting economic eval-
uation for global health trials.60 61
METHODS: ECONOMIC EVALUATION OF THE WANTAIM TRIAL
Costing data
Cost data collection is guided by the perspective adopted 
for the economic evaluation. For WANTAIM, direct and 
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indirect costs will be collected from the provider perspec-
tive and societal perspective—the latter including any 
costs incurred by pregnant women and their families. The 
different cost categories and data sources are summarised 
in table 1. A combination of top- down and bottom- up 
costing approaches will be used60 and the time horizon 
for the main trial- based economic evaluation will be 12 
months.
Provider costs are incurred by the institutions imple-
menting the PoC testing intervention across the start- up, 
implementation and monitoring phases of the trial. 
The cost data will be sourced from financial records, 
programme documents and consultation with project 
staff. A step- down costing methodology will be used, 
whereby costs from project accounts are entered into 
a customised tool created in Microsoft Excel, which is 
adapted each year to reflect the changing cost structure of 
the trial during the start- up and implementation phases.
Financial costs will be converted to economic costs, 
that is, any donated goods or volunteer time that do not 
appear in the programme accounting data will be added 
to the cost sheets and assigned a current market value.62 63 
Key informant interviews with programme leads will assist 
in identifying donated or subsidised items and in allo-
cating joint costs between programme components. The 
allocation of joint staff costs will be informed by monthly 
staff timesheets. Research costs will not be included in the 
CEA. However, start- up costs will be reported and differ-
entiated from implementation costs to enable decision- 
makers to gauge the costs associated with the initial 
activities and expenditures necessary to develop PoC 
testing and integration with standard ANC.64
Provider (treatment) costs are incurred by provincial 
health authorities, who manage ANC, delivery and 
postnatal visits; and church health services, non- state 
providers who access a mix of government and institu-
tional funds. Primary data on the average unit cost of care 
will be collected from all health facilities participating 
in the WANTAIM trial. A simple cost- capture form has 
been developed for facility data collection adapted from 
other costing studies led by members of this team.65 66 
Data from this form will be used to complement existing 
data from centre reports, patients’ records and published 
national reports relating to ANC, labour and birth care, 
and postnatal care visits. Costs of services provided will 
also be calculated using a step- down approach.67
Participant (treatment) costs are the direct and indirect 
costs of healthcare seeking incurred by women and 
their families such as medical costs, transport costs and 
the opportunity costs in terms of lost productivity due to 
care- seeking visits. These will be estimated for standard 
treatment episodes in the control arms and for treatment 
episodes in the intervention arm to gauge changes in out- 
of- pocket costs of care- seeking and time dedicated to care- 
seeking for participants. Data on the direct and indirect 
costs incurred by participants are being collected from 
all trial participants (n=4600) in both arms of the trial at 
enrolment and three follow- up visits through participant 
case report forms (CRFs). The participant cost data will 
be summed and analysed as cross- sectional data to gauge 
the economic burden borne by participants and their 
households that is alleviated due to PoC testing and treat-
ment of STIs in pregnancy.
Health service use
Health service utilisation for all trial participants in the 
intervention and control arms will be estimated using 
data collected via a take- home aide memoire and partic-
ipant CRFs. The aide memoire is provided to all partic-
ipants at recruitment, who use this tool to make notes 
about the facility visits that they make or attend between 
the WANTAIM follow- up visits. The aide memoire also 
allows them to make notes about any costs associated with 
those visits. At the WANTAIM follow- up visits, these notes 
serve as prompts for questions about service utilisation 
and costs of care- seeking, which are recorded in the CRFs.
Proposed analyses
Cost and CEAs
A base case analysis will be undertaken alongside the 
trial to estimate the cost- effectiveness of the intervention 
compared with standard care as implemented. The base 
case will include all start- up costs and implementation 
costs. Costs will be presented in current prices in PNG 
kina and international dollars (INT$). All costs will be 
adjusted for inflation using the Consumer Price Index 
for PNG and will be converted to 2021 INT$ using the 
2021 Purchasing Power Parity conversion factor for PNG. 
Costs and outcomes will be converted to present values 
using an annual discount rate of 3% in the base case, and 
annual rates of 0%, 6% and 9% in sensitivity analyses.
For the base case analysis, results will be presented 
in terms of total financial and economic costs of the 
Table 1 Cost category and data sources
Description Type of cost Data sources Sample size
Provider costs
  Costs of 
implementing 
WANTAIM




  Cost of 
providing ANC 
services
Direct Health facilities 10 health 
facilities







Indirect Patient pathway 
and health worker 
observation 
data collected 












ANC, antenatal care; N/A, not applicable; PoC, point- of- care; 
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intervention and incremental cost- effectiveness ratios 
(ICERs) for the primary outcome, that is, the propor-
tion of women and their newborns who experience 
either preterm birth and/or low birth weight. ICERs will 
be calculated as the arithmetic mean difference in cost 
between the intervention and control arms, divided by 
the arithmetic mean difference in effect. To maximise 
comparability with other trials, ICERs will also be reported 
in terms of cost per life year saved and cost per disability- 
adjusted life year (DALY) averted (see the Modelling 
section for details).
A descriptive analysis of missing data will be undertaken 
to inform the base case assumption regarding the missing 
data mechanism (the probability that missing data are 
independent or not on the observed or unobserved 
values). Appropriate methods will be used to handle 
the missing data, which may include mean imputation, 
multiple imputations, available case analysis, inverse 
probability weighting or likelihood methods.68 Sensitivity 
analyses will be conducted as appropriate.
The data on costs and outcomes for the period of trial 
follow- up will be at the individual level, allowing evalu-
ation of uncertainty of the cost- effectiveness estimates 
using non- parametric bootstrapping.69 Cost- effectiveness 
acceptability curves (CACs) will be generated to further 
describe uncertainty around the cost estimates.70 CACs 
indicate the proportion of the estimates produced by 
bootstrapping that would be ‘acceptable’ below a range 
of willingness- to- pay thresholds, where willingness to pay 
is the value placed on an additional pregnant woman 
appropriately tested for STIs in pregnancy. Sensitivity 
analyses will take into account the uncertainty in key 
parameters that may have been affected by the COVID-19 
pandemic, such as staff or drug costs.
Modelling
The base case analysis will have a time horizon of up to 12 
months. If the intervention demonstrates clinical effec-
tiveness over that period, we will employ a cohort deci-
sion analytical model to examine the cost- effectiveness 
of the intervention over a newborn’s lifetime. A Markov 
model will be used to estimate the long- term health bene-
fits, healthcare costs and cost- effectiveness of the PoC 
intervention compared with standard care, drawing on 
results of the WANTAIM trial and available published 
data. The point of entry into the model will be ‘tested for 
STIs’. There are two possible states for women: infected 
or uninfected. Women identified as infected and then 
treated may recover and stay healthy, become re- infected 
or die. Health outcomes will therefore depend on treat-
ment compliance and include live birth without infection 
(healthy infant), live birth with infection, preterm and/
or low birth weight, and neonatal death. The model will 
be used to project differences between the intervention 
and control arms in life years saved, DALYs averted and 
lifetime healthcare costs. Sensitivity analyses will also be 
conducted within this model.
Equity impact of the intervention
The equity impact of the intervention will be investi-
gated by conducting an extended CEA (E- CEA). The 
E- CEA broadens the scope of the CEA by incorporating 
health equity and financial protection considerations for 
the most vulnerable sections of the population that are 
likely to have the highest need.71 This will be done across 
three domains: by exploring improving health gains, 
with particular reference to the poorest socioeconomic 
group; reduction in the out- of- pocket expenses faced by 
households seeking care; and improved financial protec-
tion or reducing the number of households that sink into 
poverty due to catastrophic health spending.72 For the 
E- CEA, provider and participant cost data (table 1) will 
be synthesised with data on service utilisation that will 
be collected via participant CRFs that are completed at 
enrolment into the trial and at three follow- up trial visits. 
All results will be presented by socioeconomic quintiles. 
Given that socioeconomic groups may not differ greatly 
within clusters, a Multidimensional Poverty Index (MDPI) 
will be derived from socioeconomic and income data 
collected from all trial participants at enrolment. The 
use of an MDPI provides a more nuanced understanding 
of socioeconomic status of households as it takes mone-
tary and non- monetary dimensions of deprivation into 
account.73 This enables the differentiation between popu-
lation groups who may all be relatively poor in monetary 
dimensions such as income or asset ownership.74 Thus, 
the consideration of other non- monetary attributes (eg, 
housing) allows us to distinguish between households 
that are homogeneously asset or cash poor in this study 
setting.74
Scale-up and budget impact analysis
The costs and cost- effectiveness of the intervention will 
also be considered in a scale- up scenario, in which any 
start- up costs will be excluded as they are considered sunk 
costs.75 The budget impact of the scale- up scenario will 
be explored by an analysis of fiscal space for programme 
delivery using a generalised fiscal space assessment 
method76 77 and probabilistic analyses to determine a set 
of cost- effectiveness thresholds.70 78
Patient and public involvement
WANTAIM trial participants were involved in providing 
data for the study.
DISCUSSION
To our knowledge, this paper is the first protocol for the 
economic evaluation of PoC STI testing and treatment 
in pregnancy in an LMIC setting. The proposed analyses 
aim to assess the cost- effectiveness of the intervention as 
well as its affordability and equity impact. The analyses 
will adhere to international guidelines for conducting 
and reporting economic evaluation studies and provide 
transparency in how they are conducted. The findings of 
the economic evaluation will provide decision- makers in 
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PNG and similar settings evidence on the relative value for 
money of this intervention and the likely level of invest-
ment required for implementation at scale. The findings 
of this study will be disseminated through national stake-
holder meetings, conferences, peer- reviewed publications 
and policy briefs.
Dissemination
The findings of the economic evaluation of the WANTAIM 
trial will be disseminated to academic and policymaking 
communities, and the wider public, in peer- reviewed jour-
nals, and presented at relevant conferences in PNG and 
globally.
Author affiliations
1Institute for Global Health, University College London, London, UK
2The Kirby Institute, University of New South Wales, Sydney, New South Wales, 
Australia
3The Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea
4The Burnet Institute, Melbourne, Victoria, Australia
5Faculty of Health, University of Technology Sydney, Sydney, New South Wales, 
Australia
6Department of Public Health and Preventive Medicine, Ghent University, Ghent, 
Belgium
7Department of Population Health, Medical College, Aga Khan University, Nairobi, 
Kenya
8Department of Epidemiology and Preventive Medicine, Monash University, Monash, 
Victoria, Australia
9School of Medicine and Health Sciences, University of Papua New Guinea, Port 
Moresby, Papua New Guinea
10Milne Bay Provincial Health Authority, Alotau, Papua New Guinea
11Department of Medicine, The Doherty Institute, University of Melbourne, 
Melbourne, Victoria, Australia
12The Royal Women’s Hospital, Parkville, Victoria, Australia
13The University of Queensland Centre for Clinical Research, Faculty of Medicine, 
The University of Queensland, Brisbane, Queensland, Australia
14Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
15Department of Clinical Research, London School of Hygiene and Tropical 
Medicine, London, UK
16Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea
17Madang Provincial Health Authority, Madang, Papua New Guinea
18Microbiology and Infectious Diseases Department, The Royal Women's Hospital, 
Parkville, Victoria, Australia
19Department of Global Health and Development, London School of Hygiene and 
Tropical Medicine, London, UK
Twitter Nicola Low @nicolamlow and Michaela Riddell @micriddell
Acknowledgements The study team would like to thank the WANTAIM trial 
participants, health facility staff and the provincial officers in PNG.
Contributors VW, NB and OPMS led the design of the economic evaluation. NB, 
OPMS, VW, AV, WP, CM and MR contributed to data collection and acquisition for 
the economic evaluation. NB, OPMS and VW will lead the formal data analysis for 
the economic evaluation. AV, WP, CH, RG, SL, GM, LV, CM, GK, HW, SR, SNT, DMW, 
NL, RWP, PMS, MR, ML, JB, LR, JM, SB, AK- H, PJT, WP, EP, SG, JK and VW are 
members of the research team involved in conceptualisation, funding acquisition, 
methodology, data curation and/or formal analysis of the WANTAIM trial within 
which this economic evaluation is nested, and from where the outcome data for the 
economic evaluation will be used. NB was responsible for the initial drafting of this 
manuscript. All authors contributed substantially to the review of this manuscript 
and provided critical and constructive comments. All authors read and approved 
the final manuscript. NB, OPMS, VW, AV, LV, MR and SB contributed to responding to 
reviewer comments and the revision of the manuscript.
Funding This study is funded by the Joint Global Health Trials scheme (UK 
Department for International Development, Medical Research Council, Wellcome 
Trust; MR/N006089/1); National Health and Medical Research Council, Australia 
(Project Grant 1084429); and Swiss National Science Foundation Research for 
Development award (IZ07Z0_160909/1).
Competing interests None declared.
Patient and public involvement Patients and/or the public were involved in the 
design, or conduct, or reporting, or dissemination plans of this research. Refer to 
the Methods section for further details.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
ORCID iDs
Neha Batura http:// orcid. org/ 0000- 0002- 8175- 8125
Olga PM Saweri http:// orcid. org/ 0000- 0001- 5142- 8355
Andrew Vallely http:// orcid. org/ 0000- 0003- 1558- 4822
Lisa M Vallely http:// orcid. org/ 0000- 0002- 8247- 7683
Nicola Low http:// orcid. org/ 0000- 0003- 4817- 8986
REFERENCES
 1 Newman L, Rowley J, Vander Hoorn S, et al. Global estimates of 
the prevalence and incidence of four curable sexually transmitted 
infections in 2012 based on systematic review and global reporting. 
PLoS One 2015;10:e0143304.
 2 World Health Organization. Sexually transmitted infections: 
implementing the global STI strategy. World Health Organization, 
2017.
 3 Unemo M, Bradshaw CS, Hocking JS, et al. Sexually transmitted 
infections: challenges ahead. Lancet Infect Dis 2017;17:e235–79.
 4 Mullick Set al. Sexually transmitted infections in pregnancy: 
prevalence, impact on pregnancy outcomes, and approach 
to treatment in developing countries. Sex Transm Infect 
2005;81:294–302.
 5 Vallely LM, Toliman P, Ryan C, et al. Prevalence and risk factors 
of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas 
vaginalis and other sexually transmissible infections among women 
attending antenatal clinics in three provinces in Papua New Guinea: a 
cross- sectional survey. Sex Health 2016;13:420–7.
 6 Wangnapi RA, Soso S, Unger HW, et al. Prevalence and risk factors 
for Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas 
vaginalis infection in pregnant women in Papua New Guinea. Sex 
Transm Infect 2015;91:194.1–200.
 7 Gravett MG, Nelson HP, DeRouen T, et al. Independent associations 
of bacterial vaginosis and Chlamydia trachomatis infection with 
adverse pregnancy outcome. JAMA 1986;256:1899–903.
 8 Association of Chlamydia trachomatis and Mycoplasma hominis 
with intrauterine growth retardation and preterm delivery. The John 
Hopkins study of cervicitis and adverse pregnancy outcome. Am J 
Epidemiol 1989;129:1247–57.
 9 Elliott B, Brunham RC, Laga M, et al. Maternal gonococcal infection 
as a preventable risk factor for low birth weight. J Infect Dis 
1990;161:531–6.
 10 Silva MJPMdeA, Florêncio GLD, Gabiatti JRE, et al. Perinatal 
morbidity and mortality associated with chlamydial infection: a meta- 
analysis study. Braz J Infect Dis 2011;15:533–9.
 11 Rours GIJG, Duijts L, Moll HA, et al. Chlamydia trachomatis infection 
during pregnancy associated with preterm delivery: a population- 
based prospective cohort study. Eur J Epidemiol 2011;26:493–502.
 12 Johnson HL, Ghanem KG, Zenilman JM, et al. Sexually transmitted 
infections and adverse pregnancy outcomes among women 
attending inner City public sexually transmitted diseases clinics. Sex 
Transm Dis 2011;38:167–71.
 13 Kahn JG, Jiwani A, Gomez GB, et al. The cost and cost- effectiveness 
of scaling up screening and treatment of syphilis in pregnancy: a 
model. PLoS One 2014;9:e87510.
 14 Blencowe H, Cousens S, Jassir FB, et al. National, regional, and 
worldwide estimates of stillbirth rates in 2015, with trends from 2000: 
a systematic analysis. Lancet Glob Health 2016;4:e98–108.
 15 Badman SG, Vallely LM, Toliman P, et al. A novel point- of- care testing 
strategy for sexually transmitted infections among pregnant women 
 on S
eptem









pen: first published as 10.1136/bm





7Batura N, et al. BMJ Open 2021;11:e046308. doi:10.1136/bmjopen-2020-046308
Open access
in high- burden settings: results of a feasibility study in Papua New 
Guinea. BMC Infect Dis 2016;16:250–50.
 16 Vallely A, Page A, Dias S, et al. The prevalence of sexually 
transmitted infections in Papua New Guinea: a systematic review and 
meta- analysis. PLoS One 2010;5:e15586–e86.
 17 Watson- Jones D, Oliff M, Terris- Prestholt F, et al. Antenatal syphilis 
screening in sub- Saharan Africa: lessons learned from Tanzania. Trop 
Med Int Health 2005;10:934–43.
 18 Blencowe H, Cousens S, Kamb M, et al. Lives saved tool supplement 
detection and treatment of syphilis in pregnancy to reduce syphilis 
related stillbirths and neonatal mortality. BMC Public Health 2011;11 
Suppl 3:S9.
 19 Ministerial Task Force on Maternal Health in Papua New Guinea. 
Report of the Ministerial Task force on maternal health in Papua New 
Guinea. Port Moresby, Papua New Guinea: National Department of 
Health, Government of Papua New Guinea, 2009.
 20 Badman SG, Vallely LM, Toliman P, et al. A novel point- of- care testing 
strategy for sexually transmitted infections among pregnant women 
in high- burden settings: results of a feasibility study in Papua New 
Guinea. BMC Infect Dis 2016;16:250.
 21 Toskin I, Blondeel K, Peeling RW, et al. Advancing point of care 
diagnostics for the control and prevention of STIs: the way forward. 
Sex Transm Infect 2017;93:S81–8.
 22 Vallely LM, Toliman P, Ryan C, et al. Performance of syndromic 
management for the detection and treatment of genital Chlamydia 
trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis 
among women attending antenatal, well woman and sexual health 
clinics in Papua New Guinea: a cross- sectional study. BMJ Open 
2017;7:e018630.
 23 Peeling RW. Testing for sexually transmitted infections: a brave new 
world? Sex Transm Infect 2006;82:425–30.
 24 Mabey DC, Sollis KA, Kelly HA, et al. Point- Of- Care tests to 
strengthen health systems and save newborn lives: the case of 
syphilis. PLoS Med 2012;9:e1001233.
 25 Marks M, Mabey DC. The introduction of syphilis point of care tests 
in resource limited settings. Expert Rev Mol Diagn 2017;17:321–5.
 26 Swartzendruber A, Steiner RJ, Adler MR, et al. Introduction of rapid 
syphilis testing in antenatal care: a systematic review of the impact 
on HIV and syphilis testing uptake and coverage. Int J Gynaecol 
Obstet 2015;130 Suppl 1:S15–21.
 27 Phang Romero Casas C, Martyn- St James M, Hamilton J, et al. 
Rapid diagnostic test for antenatal syphilis screening in low- income 
and middle- income countries: a systematic review and meta- 
analysis. BMJ Open 2018;8:e018132.
 28 Nuñez- Forero L, Moyano- Ariza L, Gaitán- Duarte H, et al. Diagnostic 
accuracy of rapid tests for sexually transmitted infections in 
symptomatic women. Sex Transm Infect 2016;92:24–8.
 29 Pearce DM, Styles DN, Hardick JP, et al. A new rapid molecular 
point- of- care assay for Trichomonas vaginalis: preliminary 
performance data. Sex Transm Infect 2013;89:495–7.
 30 Sabidó M, Hernández G, González V, et al. Clinic- Based evaluation 
of a rapid point- of- care test for detection of Chlamydia trachomatis 
in specimens from sex workers in Escuintla, Guatemala. J Clin 
Microbiol 2009;47:475–6.
 31 Hegazy MM, El- Tantawy NL, Soliman MM, et al. Performance 
of rapid immunochromatographic assay in the diagnosis of 
trichomoniasis vaginalis. Diagn Microbiol Infect Dis 2012;74:49–53.
 32 Benzaken AS, Galban EG, Antunes W, et al. Diagnosis of gonococcal 
infection in high risk women using a rapid test. Sex Transm Infect 
2006;82 Suppl 5:v26–8.
 33 Vallely AJ, Pomat WS, Homer C, et al. Point- Of- Care testing 
and treatment of sexually transmitted infections to improve birth 
outcomes in high- burden, low- income settings: study protocol for 
a cluster randomized crossover trial (the wantaim trial, Papua New 
Guinea). Wellcome Open Res 2019;4:53.
 34 Saweri OPM, Batura N, Al Adawiyah R, et al. Economic evaluation 
of point- of- care testing and treatment for sexually transmitted and 
genital infections in pregnancy in low- and middle- income countries: 
a systematic review. PLoS One 2021;16:e0253135.
 35 Kuznik A, Lamorde M, Nyabigambo A, et al. Antenatal 
syphilis screening using point- of- care testing in sub- Saharan 
African countries: a cost- effectiveness analysis. PLoS Med 
2013;10:e1001545.
 36 Rydzak CE, Goldie SJ. Cost- effectiveness of rapid point- of- care 
prenatal syphilis screening in sub- Saharan Africa. Sex Transm Dis 
2008;35:775–84.
 37 Vickerman P, Peeling RW, Terris- Prestholt F, et al. Modelling the 
cost- effectiveness of introducing rapid syphilis tests into an antenatal 
syphilis screening programme in Mwanza, Tanzania. Sex Transm 
Infect 2006;82 Suppl 5:v38–43.
 38 Blandford JM, Gift TL, Vasaikar S, et al. Cost- effectiveness of 
on- site antenatal screening to prevent congenital syphilis in rural 
eastern Cape Province, Republic of South Africa. Sex Transm Dis 
2007;34:S61–6.
 39 Romoren M, Hussein F, Steen TW, et al. Costs and health 
consequences of chlamydia management strategies among pregnant 
women in sub- Saharan Africa. Sex Transm Infect 2007;83:558–66.
 40 Larson BA, Lembela- Bwalya D, Bonawitz R, et al. Finding a needle in 
the haystack: the costs and cost- effectiveness of syphilis diagnosis 
and treatment during pregnancy to prevent congenital syphilis in 
Kalomo district of Zambia. PLoS One 2014;9:e113868.
 41 Shelley KD, Ansbro Éimhín M, Ncube AT, et al. Scaling down to scale 
up: a health economic analysis of integrating point- of- care syphilis 
testing into antenatal care in Zambia during pilot and national rollout 
implementation. PLoS One 2015;10:e0125675.
 42 Owusu- Edusei K, Gift TL, Ballard RC. Cost- effectiveness of a dual 
non- treponemal/treponemal syphilis point- of- care test to prevent 
adverse pregnancy outcomes in sub- Saharan Africa. Sex Transm Dis 
2011;38:997–1003.
 43 Sweeney S, Mosha JF, Terris- Prestholt F, et al. The costs of 
accessible quality assured syphilis diagnostics: informing quality 
systems for rapid syphilis tests in a Tanzanian setting. Health Policy 
Plan 2014;29:633–41.
 44 Bristow CC, Larson E, Anderson LJ, et al. Cost- effectiveness of HIV 
and syphilis antenatal screening: a modelling study. Sex Transm 
Infect 2016;92:340–6.
 45 Mallma P, Garcia P, Carcamo C, et al. Rapid syphilis testing is 
cost- effective even in low- prevalence settings: the CISNE- PERU 
experience. PLoS One 2016;11:e0149568.
 46 Obure CD, Gaitan- Duarte H, Losada Saenz R, Saenz RL, et al. A 
comparative analysis of costs of single and dual rapid HIV and 
syphilis diagnostics: results from a randomised controlled trial in 
Colombia. Sex Transm Infect 2017;93:482–6.
 47 Levin CE, Steele M, Atherly D, et al. Analysis of the operational costs 
of using rapid syphilis tests for the detection of maternal syphilis in 
Bolivia and Mozambique. Sex Transm Dis 2007;34:S47–54.
 48 Terris- Prestholt F, Vickerman P, Torres- Rueda S, et al. The cost- 
effectiveness of 10 antenatal syphilis screening and treatment 
approaches in Peru, Tanzania, and Zambia. Int J Gynaecol Obstet 
2015;130 Suppl 1:S73–80.
 49 Kuznik A, Muhumuza C, Komakech H, et al. Antenatal syphilis 
screening using point- of- care testing in low- and middle- income 
countries in Asia and Latin America: a cost- effectiveness analysis. 
PLoS One 2015;10:e0127379.
 50 Saweri O, Batura N, Al Adawiyah R. The cost and cost- effectiveness 
of point- of- care testing and treatment for sexually transmitted and 
genital infections in pregnancy in low- and middle- income countries. 
Basel: International Health Economics Assocation Congress, 2019.
 51 Wang H, Liddell CA, Coates MM, et al. Global, regional, and national 
levels of neonatal, infant, and under-5 mortality during 1990–2013: a 
systematic analysis for the global burden of disease study 2013. The 
Lancet 2014;384:957–79.
 52 Kassebaum NJ, Bertozzi- Villa A, Coggeshall MS, et al. Global, 
regional, and national levels and causes of maternal mortality during 
1990–2013: a systematic analysis for the global burden of disease 
study 2013. The Lancet 2014;384:980–1004.
 53 Mola G, Kirby B. Discrepancies between national maternal mortality 
data and international estimates: the experience of Papua New 
Guinea. Reprod Health Matters 2013;21:191–202.
 54 Mola G. Manual of standard managements in obstetrics and 
gynaecology for doctors. In: HEOs and nurses in Papua New Guinea. 
Sixth ed, 2010.
 55 Government of Papua New Guinea. National health plan 2011–2020: 
national department of health, government of Papua New Guinea, 
2010.
 56 Hou X, Khan MM, Pulford J. Service delivery by health facilities in 
Papua New Guinea: report based on a countrywide health facility 
survey. The World Bank, 2018.
 57 World Health Organization. Papua new Guinea- WHO country 
cooperation strategy 2016-2020. Manila: WHO Regional Office for 
the Western Pacific, 2016.
 58 World Health Organization. The world health report 2006: working 
together for health. World Health Organization, 2006.
 59 Hou XK, Mahmud M, Pulford J. Service delivery by health facilities 
in Papua New Guinea : report based on a countrywide health facility 
survey (English. The WorldBank Group, 2018.
 60 Vassall A, Sweeney S, Kahn J. Reference case for estimating the 
costs of global health services and interventions, 2017.
 61 Husereau D, Drummond M, Petrou S, et al. Consolidated Health 
Economic Evaluation Reporting Standards (CHEERS)--explanation 
and elaboration: a report of the ISPOR Health Economic Evaluation 
 on S
eptem









pen: first published as 10.1136/bm





8 Batura N, et al. BMJ Open 2021;11:e046308. doi:10.1136/bmjopen-2020-046308
Open access 
Publication Guidelines Good Reporting Practices Task Force. Value 
Health 2013;16:231–50.
 62 Drummond MF, Sculpher MJ, Claxton K. Methods for the economic 
evaluation of health care programmes. Oxford university press, 2015.
 63 Batura N, Pulkki- Brännström A- M, Agrawal P, et al. Collecting and 
analysing cost data for complex public health trials: reflections on 
practice. Glob Health Action 2014;7:23257.
 64 Mogyorosy Z, Smith P. The main methodological issues in costing 
health care services: a literature review. York, UK: Centre for Health 
Economics, 2005.
 65 Wiseman V, Mangham LJ, Cundill B, et al. A cost- effectiveness 
analysis of provider interventions to improve health worker practice 
in providing treatment for uncomplicated malaria in Cameroon: a 
study protocol for a randomized controlled trial. Trials 2012;13:4.
 66 Wiseman V, Ogochukwu E, Emmanuel N, et al. A cost- effectiveness 
analysis of provider and community interventions to improve the 
treatment of uncomplicated malaria in Nigeria: study protocol for a 
randomized controlled trial. Trials 2012;13:81.
 67 Conteh L, Walker D. Cost and unit cost calculations using step- down 
accounting. Health Policy Plan 2004;19:127–35.
 68 Faria R, Gomes M, Epstein D, et al. A guide to handling missing 
data in cost- effectiveness analysis conducted within randomised 
controlled trials. Pharmacoeconomics 2014;32:1157–70.
 69 Nixon RM, Wonderling D, Grieve RD. Non‐parametric methods 
for cost- effectiveness analysis: the central limit theorem and the 
bootstrap compared. Health Econ 2010;19:316–33.
 70 Fenwick E, Claxton K, Sculpher M. Representing uncertainty: 
the role of cost- effectiveness acceptability curves. Health Econ 
2001;10:779–87.
 71 Verguet S, Murphy S, Anderson B, et al. Public finance of rotavirus 
vaccination in India and Ethiopia: an extended cost- effectiveness 
analysis. Vaccine 2013;31:4902–10.
 72 Verguet S, Kim JJ, Jamison DT. Extended cost- effectiveness analysis 
for health policy assessment: a tutorial. Pharmacoeconomics 
2016;34:913–23.
 73 Bourguignon F, Chakravarty SR. The measurement of 
multidimensional poverty. poverty. Social Exclusion and Stochastic 
Dominance: Springer, 2019: 83–107.
 74 Alkire S, Roche JM, Ballon P. Multidimensional poverty measurement 
and analysis. USA: Oxford University Press, 2015.
 75 Honeycutt AA, Khavjou OA, Jones DJ, et al. Helping the 
noncompliant child: an assessment of program costs and cost- 
effectiveness. J Child Fam Stud 2015;24:499–504.
 76 Tandon A, Cashin C. Assessing public expenditure on health from a 
fiscal space perspective. Washington DC, USA: World Bank, 2010.
 77 Heller PS. The prospects of creating 'fiscal space' for the health 
sector. Health Policy Plan 2006;21:75–9.
 78 Briggs A. Probabilistic analysis of cost- effectiveness models: 













pen: first published as 10.1136/bm
jopen-2020-046308 on 12 A
ugust 2021. D
ow
nloaded from
 
